The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome

Abstract

Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia-inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in HF. Although several trials investigated statins treatment effects on HF in general, some evidence exists about the role that these drugs can have in the progression of the disease in the specific category of HF patients affected by MetS. In this review the possible positive effects of the statins treatment in this specific subset of patients are discussed.

Angiographic Evaluation of Coronary Microvascular Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction

“…Regarded such premises, the new HFPEF paradigm supports the use of statins that exert rapid and direct effects on endothelial redox balance, which are independent of low‐density lipoprotein lowering and consist of reduced superoxide anion production and restored NO bioavailability. Several studies in hypercholesterolemic patients with CAD have demonstrated that lipid lowering therapy restores coronary endothelium‐dependent vasodilatation and increase myocardial perfusion .…”

Dietary strategy for prevention and management of dyslipidemia: international guidelines

“…It reaffirms the central and irreplaceable role of statins, and represents the drug of choice for blood the control of cholesterol. [36][37][38] The guidelines clearly state that the benefits trials are independent from the type of statin and, therefore, the choice of the latter must be considered in relation to the entity of the reduction required in the individual patient, as well as the efficacy and tolerability to the molecule.…”

Dietary strategy for prevention and management of dyslipidemia: international guidelines

“…It reaffirms the central and irreplaceable role of statins, and represents the drug of choice for blood the control of cholesterol. [36][37][38] The guidelines clearly state that the benefits trials are independent from the type of statin and, therefore, the choice of the latter must be considered in relation to the entity of the reduction required in the individual patient, as well as the efficacy and tolerability to the molecule.…”